KeChow Pharma (China)

Homepage: kechowpharma.com

Alternate names: KeChow Pharma, Shanghai KeChow Pharma, 上海科州药物股份有限公司, 科州药物

ROR: 03c3tz828

OpenAlex ID: I4405263159

Polycysteine as a new type of radio-protector ameliorated tissue injury through inhibiting ferroptosis in mice

2021 · Junling Zhang, Kui Li, et al. · Cell Death and Disease · 39

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma

2024 · Xiaoting Wei, Zhengyun Zou, et al. · European Journal of Cancer · 36

Tas2R activation relaxes airway smooth muscle by release of Gα t targeting on AChR signaling

2022 · Yu-Wei Zhou, Jie Sun, et al. · Proceedings of the National Academy of Sciences · 31

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

2023 · Xuan Wang, Zhiguo Luo, et al. · BMC Medicine · 25

Radioprotective effects and mechanism of HL-003 on radiation-induced salivary gland damage in mice

2022 · Jingming Ren, Rong Huang, et al. · Scientific Reports · 21

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

2023 · Yahong Liu, Ying Cheng, et al. · Frontiers in Pharmacology · 18

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

2022 · Qian Zhao, Teng Wang, et al. · Frontiers in Pharmacology · 13

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

2024 · Yuankai Shi, Xiaohong Han, et al. · Experimental Hematology and Oncology · 10

Diselenide-based nanoparticles enhancing the radioprotection to the small intestine of mice

2025 · Yichi Huang, Jiaze Li, et al. · Journal of Nanobiotechnology · 8

Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

2023 · Lu Si, Zhengyun Zou, et al. · Journal of Clinical Oncology · 7

Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

2026 · Zhichao Wang, Jingxuan Huang, et al. · Clinical Cancer Research · 3

Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

2024 · Xiaoting Wei, Zhengyun Zou, et al. · Journal of Clinical Oncology · 3

1378P Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study

2023 · Y-K. Shi, Y. Zheng, et al. · Annals of Oncology · 3

A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated BRAF V600E -mutant metastatic colorectal cancer.

2026 · Ting Xu, Jian Li, et al. · Journal of Clinical Oncology · 1

A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy.

2024 · Xiaoting Wei, Weizhen Zhang, et al. · Journal of Clinical Oncology · 1

A phase II study of tunlametinib in combination with vemurafenib in patients with BRAF V600-mutant advanced melanoma.

2024 · Xiaoting Wei, Yu Chen, et al. · Journal of Clinical Oncology · 1

Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro

2023 · Gongchao Huang, Wenqin Zhang, et al. · Asian Biomedicine

Works count: 17

Citation count: 464